<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Granulocyte-colony stimulating factor (G-CSF) is an endogenous <z:chebi fb="0" ids="25905">peptide hormone</z:chebi> of the hematopoietic system that has entered Phase I/II clinical trials for treatment of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Severe intraoperative <z:hpo ids='HP_0002615'>hypotension</z:hpo> can lead to global <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and apoptotic neuron loss within the hippocampus </plain></SENT>
<SENT sid="2" pm="."><plain>We tested G-CSF in a rat model of global <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Global <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was induced in male Sprague-Dawley rats (280-330 g) with the 2-vessel occlusion model (hemorrhagic <z:hpo ids='HP_0002615'>hypotension</z:hpo> to a mean arterial pressure of 30-35 mm Hg and bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 8 min) </plain></SENT>
<SENT sid="4" pm="."><plain>Three groups of animals were used: global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> without treatment (GI, n=49), global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> with G-CSF treatment (GI+G-CSF, n=42), and sham surgery (Sham, n=26) </plain></SENT>
<SENT sid="5" pm="."><plain>Rats in the treatment group received G-CSF (50 mug/kg, subcutaneously) 12 h before surgery, on the day of surgery, and on postoperative Day 1 and were euthanized on Days 2, 3, and 14 </plain></SENT>
<SENT sid="6" pm="."><plain>Mild <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> was observed in <z:hpo ids='HP_0000001'>all</z:hpo> groups </plain></SENT>
<SENT sid="7" pm="."><plain>T-maze testing for spontaneous alternation demonstrated initial improvement in the G-CSF treatment group but no long-term benefit </plain></SENT>
<SENT sid="8" pm="."><plain>Measurement of daily body weight demonstrated an initial trend toward improvement in the G-CSF group </plain></SENT>
<SENT sid="9" pm="."><plain>Quantitative Nissl histology of the hippocampus demonstrated equivalent outcomes on Days 3 and 14, which was supported by quantitative TUNEL stain </plain></SENT>
<SENT sid="10" pm="."><plain>Immunohistochemistry and Western blot demonstrated an initial increase in phosphorylated-AKT in the GI+G-CSF group on Day 2 </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude that G-CSF treatment is associated with transient early improvement in neurobehavioral outcomes after global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> complicated by mild <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, but no long-term protection </plain></SENT>
</text></document>